TWI661826B - 降低主要不良心血管事件之組合物及方法 - Google Patents

降低主要不良心血管事件之組合物及方法 Download PDF

Info

Publication number
TWI661826B
TWI661826B TW103142498A TW103142498A TWI661826B TW I661826 B TWI661826 B TW I661826B TW 103142498 A TW103142498 A TW 103142498A TW 103142498 A TW103142498 A TW 103142498A TW I661826 B TWI661826 B TW I661826B
Authority
TW
Taiwan
Prior art keywords
individual
naltrexone
bupropion
mace
treatment
Prior art date
Application number
TW103142498A
Other languages
English (en)
Chinese (zh)
Other versions
TW201607536A (zh
Inventor
裴斯頓 克雷森
克里斯丁 泰勒
Original Assignee
美商歐瑞根治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI661826(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商歐瑞根治療有限公司 filed Critical 美商歐瑞根治療有限公司
Publication of TW201607536A publication Critical patent/TW201607536A/zh
Application granted granted Critical
Publication of TWI661826B publication Critical patent/TWI661826B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW103142498A 2013-12-06 2014-12-05 降低主要不良心血管事件之組合物及方法 TWI661826B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US61/913,216 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US61/914,938 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US61/984,580 2014-04-25
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations
US14/322,810 2014-07-02

Publications (2)

Publication Number Publication Date
TW201607536A TW201607536A (zh) 2016-03-01
TWI661826B true TWI661826B (zh) 2019-06-11

Family

ID=52575014

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103142498A TWI661826B (zh) 2013-12-06 2014-12-05 降低主要不良心血管事件之組合物及方法

Country Status (33)

Country Link
US (9) US8969371B1 (cg-RX-API-DMAC7.html)
EP (2) EP4005571A1 (cg-RX-API-DMAC7.html)
JP (2) JP6665094B2 (cg-RX-API-DMAC7.html)
KR (3) KR20230152800A (cg-RX-API-DMAC7.html)
CN (3) CN117159547A (cg-RX-API-DMAC7.html)
AU (1) AU2014360492A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016012755A2 (cg-RX-API-DMAC7.html)
CA (1) CA2932127C (cg-RX-API-DMAC7.html)
CL (1) CL2016001362A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160313A (cg-RX-API-DMAC7.html)
CY (1) CY1125114T1 (cg-RX-API-DMAC7.html)
DK (1) DK3076971T3 (cg-RX-API-DMAC7.html)
EA (1) EA201690964A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16057765A (cg-RX-API-DMAC7.html)
ES (1) ES2903391T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220058T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057551T2 (cg-RX-API-DMAC7.html)
IL (3) IL300870A (cg-RX-API-DMAC7.html)
JO (1) JOP20140344B1 (cg-RX-API-DMAC7.html)
LT (1) LT3076971T (cg-RX-API-DMAC7.html)
MX (2) MX389742B (cg-RX-API-DMAC7.html)
PE (1) PE20161034A1 (cg-RX-API-DMAC7.html)
PL (1) PL3076971T3 (cg-RX-API-DMAC7.html)
PT (1) PT3076971T (cg-RX-API-DMAC7.html)
RS (1) RS62846B1 (cg-RX-API-DMAC7.html)
RU (1) RU2711638C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201808055QA (cg-RX-API-DMAC7.html)
SI (1) SI3076971T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000231A1 (cg-RX-API-DMAC7.html)
TW (1) TWI661826B (cg-RX-API-DMAC7.html)
UY (1) UY35864A (cg-RX-API-DMAC7.html)
WO (1) WO2015085044A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201603831B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
PE20150358A1 (es) * 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
EP3493574B1 (en) * 2016-08-11 2023-04-12 Huawei Technologies Co., Ltd. Wireless communication method based on unlicensed frequency spectrum, and base station and terminal device
US20250332152A1 (en) * 2021-12-09 2025-10-30 Incarda Therapeutics, Inc. Inhaled therapy for cardiac arrhythmia
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058272T3 (es) 1987-05-04 1994-11-01 Lilly Co Eli Fluoxetina util para el tratamiento de la diabetes.
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
EP0782445B1 (en) 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
ATE344668T1 (de) 1996-05-07 2006-11-15 Pliva Istrazivanje I Razvoj D Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
IL127715A (en) 1996-06-28 2004-07-25 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
KR20010030860A (ko) 1997-10-03 2001-04-16 캐리 메디컬 코퍼레이션 니코틴 리셉터 길항제, 및 항-진정제 또는 항-불안 약물을함유하는 니코틴 중독치료용 조성물
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
JP2003509349A (ja) 1999-09-15 2003-03-11 エラン ファーマシューティカルズ，インコーポレイテッド ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CA2397726A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
EP1414418A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
BR0309969A (pt) 2002-05-17 2005-04-26 Merck Patent Gmbh Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos
KR20110043664A (ko) 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7273884B2 (en) 2002-09-13 2007-09-25 Eisai, Inc. Method of treating tremors
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
BRPI0410271A (pt) 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
HRP20100368T1 (hr) 2003-09-25 2010-08-31 Euro-Celtique S.A. Farmaceutske kombinacije hidrokodona i naltreksona
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CN101001619A (zh) 2004-08-03 2007-07-18 奥雷西根治疗公司 影响体重减轻的安非他酮和第二化合物的组合物
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AR058239A1 (es) 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Metodos para tratar trastornos de ansiedad
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
JP5478245B2 (ja) 2006-06-05 2014-04-23 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソンの徐放型配合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20150029762A (ko) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
WO2012075453A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caroline M. Apovian etc.;"A Randomized,Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors(COR-Ⅱ)";Obesity,2013,21(5),935-943. *

Also Published As

Publication number Publication date
US20150182524A1 (en) 2015-07-02
NZ720620A (en) 2022-03-25
LT3076971T (lt) 2022-02-10
KR20230152800A (ko) 2023-11-03
CL2016001362A1 (es) 2017-01-06
US20190314363A1 (en) 2019-10-17
CA2932127C (en) 2023-05-02
US10828294B2 (en) 2020-11-10
HUE057551T2 (hu) 2022-05-28
CN117159547A (zh) 2023-12-05
CR20160313A (es) 2018-01-26
JP7204634B2 (ja) 2023-01-16
US20250144089A1 (en) 2025-05-08
US20160310485A1 (en) 2016-10-27
SI3076971T1 (sl) 2022-04-29
US10835527B2 (en) 2020-11-17
EP3076971B1 (en) 2021-10-20
CN105899210A (zh) 2016-08-24
AU2014360492A1 (en) 2016-06-23
UY35864A (es) 2015-07-31
BR112016012755A2 (pt) 2017-08-08
SG10201808055QA (en) 2018-10-30
JP2016539164A (ja) 2016-12-15
PE20161034A1 (es) 2016-11-13
CN114404419A (zh) 2022-04-29
PT3076971T (pt) 2022-01-26
RU2711638C2 (ru) 2020-01-17
JP6665094B2 (ja) 2020-03-13
US20190374535A1 (en) 2019-12-12
EP3076971A1 (en) 2016-10-12
US9801875B2 (en) 2017-10-31
IL282117A (en) 2021-05-31
WO2015085044A1 (en) 2015-06-11
EP3076971A4 (en) 2017-06-28
US20150366860A1 (en) 2015-12-24
IL245919A0 (en) 2016-07-31
US20180243288A1 (en) 2018-08-30
KR102472432B1 (ko) 2022-11-30
CA2932127A1 (en) 2015-06-11
JP2020037593A (ja) 2020-03-12
US11998542B2 (en) 2024-06-04
IL300870A (en) 2023-04-01
US10231962B2 (en) 2019-03-19
RS62846B1 (sr) 2022-02-28
US20210069181A1 (en) 2021-03-11
EA201690964A1 (ru) 2016-12-30
ES2903391T3 (es) 2022-04-01
MX2022001251A (es) 2022-02-23
JOP20140344B1 (ar) 2021-08-17
PL3076971T3 (pl) 2022-04-04
DK3076971T3 (da) 2022-01-24
ECSP16057765A (es) 2017-02-24
US8969371B1 (en) 2015-03-03
ZA201603831B (en) 2023-05-31
TW201607536A (zh) 2016-03-01
MX2016007231A (es) 2016-08-04
US9119850B2 (en) 2015-09-01
MX389742B (es) 2025-03-20
US10231964B2 (en) 2019-03-19
HRP20220058T1 (hr) 2022-04-15
TN2016000231A1 (en) 2017-10-06
KR20160095076A (ko) 2016-08-10
KR20220165791A (ko) 2022-12-15
EP4005571A1 (en) 2022-06-01
CY1125114T1 (el) 2023-06-09

Similar Documents

Publication Publication Date Title
TWI661826B (zh) 降低主要不良心血管事件之組合物及方法
US11139056B2 (en) Methods of treating overweight and obesity
NZ720620B2 (en) Compositions and methods for reducing major adverse cardiovascular events
KR20260004593A (ko) 과체중 및 비만의 치료 방법